Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents in US Patients Undergoing Coronary Revascularization: 2-Year Outcomes From the BIOFLOW VII Trial
The 2-year BIOFLOW VII results demonstrate the durability of efficacy and safety of ultrathin BP SES. Favorably low rates of ischemia-driven target lesion revascularization and definite late/very late stent thrombosis were concordant with prior trials with ultrathin BP SES.
Authors
- David E. Kandzari (ORCID: https://orcid.org/0000-0002-0868-6655)
- Mark F. Picone
- Robert C. Stoler (ORCID: https://orcid.org/0000-0002-8946-0163)
- Itsik Ben-Dor
- Hector M. Garcia-Garcia
- Santiago A. Garcia
- John Wang
Institutions
- MedStar Washington Hospital Center (US)
- Piedmont Atlanta Hospital (US)
- MedStar Union Memorial Hospital (US)
- Christ Hospital (US)
- Austin Regional Clinic (US)
- Baylor Jack and Jane Hamilton Heart and Vascular Hospital (US)
- Research Network (United States) (US)
- Christ Hospital (US)
Publication Details
- Journal
- Journal of the Society for Cardiovascular Angiography & Interventions
- Published
- 2026-02-03
- DOI
- https://doi.org/10.1016/j.jscai.2025.104167
- Primary Topic
- Coronary Interventions and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00